<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414542</url>
  </required_header>
  <id_info>
    <org_study_id>H-11</org_study_id>
    <nct_id>NCT02414542</nct_id>
  </id_info>
  <brief_title>Minima Clinical Study</brief_title>
  <official_title>A Multicentre, Prospective, Observational Clinical Study Evaluating the Outcomes of a Cementless Metaphyseal Short Stem After Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-marketing clinical study,international, multi-centre, prospective, observational. The&#xD;
      investigation will be carried out in 2 sites in Europe for a maximum total number of 160&#xD;
      patients.The aim of this study is to assess clinical, radiographic and subjective outcomes&#xD;
      after hip arthroplasty with a cementless metaphyseal MINIMA short stem, define the&#xD;
      survivorship of the implant and identify possible risk factors that may lead to failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Harris Hip Score (HHS)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UCLA activity score</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time up and go test (TUG)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Range of motion (ROM)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hip disability and Osteoarthritis Outcome Score (HOOS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant stability measured by radiographic evaluations</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revision rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of device-related Adverse Events/Serious Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mid-term clinical outcomes: Harris Hip Score and Hip disability and Osteoarthritis Outcome Score (HOOS)</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of device-related Adverse Events and Serious Adverse Events</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Survival rate (Kaplan Meier)</measure>
    <time_frame>60 months</time_frame>
  </other_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MINIMA stem</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected for recruitment into the study from the general diagnosis&#xD;
        population of patients requiring a primary hip arthroplasty, due to symptomatic painful&#xD;
        degenerative joint diseases (NDJD). Patients requiring a revision of a previous failed stem&#xD;
        cannot be enrolled into the clinical evaluation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Both genders&#xD;
&#xD;
          2. Age â‰¥ 18 years old&#xD;
&#xD;
          3. Life expectancy over 5 years&#xD;
&#xD;
          4. Any race&#xD;
&#xD;
          5. Ambulatory patients&#xD;
&#xD;
          6. Painful primary coxarthrosis&#xD;
&#xD;
          7. Painful secondary coxarthrosis&#xD;
&#xD;
          8. Avascular necrosis&#xD;
&#xD;
          9. Willingness to comply with rehabilitation and study evaluation and ability to return&#xD;
             for follow-up visits&#xD;
&#xD;
         10. Signed study-specific Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body mass index over 28 kg/m2 for the modular version&#xD;
&#xD;
          2. Requiring revision of previous standard femoral stem&#xD;
&#xD;
          3. Symptomatic OA of the knees, spine, ankles or contralateral hip, if it can interfere&#xD;
             with the evaluation of the target hip according to the Investigator&#xD;
&#xD;
          4. Previous hip replacement (resurfacing or THR) on the contralateral side and whose&#xD;
             outcome is achieving an HHS&lt; 60 points&#xD;
&#xD;
          5. Significant proven or suspicious infection of the target hip&#xD;
&#xD;
          6. Any serious infectious disease before the study according to the Investigator&#xD;
&#xD;
          7. Muscular insufficiency that may compromise functional recovery&#xD;
&#xD;
          8. Proven osteopenia and osteoporosis severe enough to compromise the stem support&#xD;
             according to the Investigator&#xD;
&#xD;
          9. Known or suspicious hypersensitivity to the metal of the implant&#xD;
&#xD;
         10. Recurrent medical history of immune-mediated reactions or other systemic immune&#xD;
             disorders&#xD;
&#xD;
         11. Vascular insufficiency or peripheral neuropathy of lower limbs severe enough to&#xD;
             interfere with the study evaluation according to the Investigator&#xD;
&#xD;
         12. Current treatment or treatment for any malignancy within the previous 2 years before&#xD;
             the preoperative visit&#xD;
&#xD;
         13. Previous organ transplant&#xD;
&#xD;
         14. Any intercurrent chronic disease or condition that may interfere with the completion&#xD;
             of the 60-month follow-up, such as liver disease, severe coronary disease, or other&#xD;
             clinically significant condition that the Investigator feels may affect the study&#xD;
             evaluation&#xD;
&#xD;
         15. Known co-existent medical condition where death is anticipated within five years due&#xD;
             to the pre-existing medical condition&#xD;
&#xD;
         16. Any clinically significant finding that would place the patient at health risk, impact&#xD;
             the study, or affect the completion of the study&#xD;
&#xD;
         17. Current alcoholism, and/or any known current addiction to pain medications or drugs&#xD;
&#xD;
         18. Any psychiatric illness that would prevent comprehension of the details and nature of&#xD;
             the study&#xD;
&#xD;
         19. Participation in any experimental drug/device study within the 6 months prior to the&#xD;
             preoperative visit&#xD;
&#xD;
         20. Unwillingness or inability to comply with rehabilitation and to return for follow-up&#xD;
             visits&#xD;
&#xD;
         21. Women of childbearing potential who are pregnant, nursing, or planning to become&#xD;
             pregnant, and those who do not agree to remain on an acceptable method of birth&#xD;
             control throughout the entire study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luigi Zagra</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.R.C.C.S. Galeazzi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>I.R.C.C.S. Galeazzi</name>
      <address>
        <city>Milano</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

